21 July 2020>: Articles
High-Dose Prednisone for Treatment of Autoimmune Pancreatitis in a Patient with Coronavirus Disease 2019 (COVID-19) due to Infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Unusual clinical course, Unusual setting of medical care
Hammad Liaquat A* , Brittney Shupp B , Sarina Kapoor C , Ayaz Matin ADOI: 10.12659/AJCR.926475
Am J Case Rep 2020; 21:e926475
Table 2. Studies demonstrating outcomes of corticosteroid treatment in patients with coronavirus disease 2019 (COVID-19) due to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Outbreak | Participants | Methods | Outcomes related to steroid use | Ref |
---|---|---|---|---|
SER-CoV-2 | 138 hospitalized patients with confirmed COVID-19 infection, including 45% who received methylprednisolone | Reviewed clinical data of COVID-19 patients to identify, analyze, and compare patient characteristics and treatment outcomes | No effective outcomes were observed | []7 |
41 hospitalized patients with confirmed COVID-19 infection, including 22% who received methylprednisolone | Reviewed clinical data of COVID-19 patients to identify, analyze, and compare patient characteristics, radiographic features, and laboratory data | Methylprednisolone was administered if patient was diagnosed with severe community acquired pneumonia, but no effective outcomes were observed | []22 | |
201 hospitalized patients with confirmed COVID-19 infection, including 30.8% who received methylprednisolone | Reviewed clinical data of COVID-19 patients to identify, analyze, and compare patient characteristics, radiographic features, and laboratory data | Death rates in ARDS patients who did and did not receive methylprednisolone were 46% and 61.8%, respectively | []23 | |
15 hospitalized patients with critical COVID-19 pneumonia admitted to the ICU | Initiated corticosteroid treatment after ICU stay of an average of 9.5 days and followed up on patient outcomes | Use of corticosteroids did not improve ICU mortality. No conclusion on corticosteroid usage could be reached due to small sample size and lack of a matched control group | []21 | |
46 hospitalized patients with severe COVID-19 pneumonia, including 26 who received extra low-dose methylprednisolone treatment | Compared the clinical outcomes of patients receiving low dose methylprednisolone treatment with a control group that received the same treatment regimen without methylprednisolone | Use of low dose and short term methylprednisolone treatment early in the disease course was associated with better outcomes in severe COVID-19 patients including shorter supplemental oxygen use, reduced need for mechanical ventilation, and shorter ICU and hospitalization stay | []20 |